Anti-inflammatory therapies in myocardial infarction: failures, hopes, and challenges.

about

A New Era of Targeting Pathogenic Immune Mechanisms in Cardiovascular Disease

P2860

Q58202790-C9FBDC97-5F46-44F9-8B6E-6BCF8D84969B

P2860

Anti-inflammatory therapies in myocardial infarction: failures, hopes, and challenges.

Item

http://www.wikidata.org/entity/Q48113765

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Anti-inflammatory therapies in myocardial infarction: failures, hopes, and challenges.

@en

Anti-inflammatory therapies in myocardial infarction: failures, hopes, and challenges.

@nl

type

Item

label

Anti-inflammatory therapies in myocardial infarction: failures, hopes, and challenges.

@en

Anti-inflammatory therapies in myocardial infarction: failures, hopes, and challenges.

@nl

prefLabel

Anti-inflammatory therapies in myocardial infarction: failures, hopes, and challenges.

@en

Anti-inflammatory therapies in myocardial infarction: failures, hopes, and challenges.

@nl

P1476

Anti-inflammatory therapies in myocardial infarction: failures, hopes, and challenges.

@en

P2093

Shuaibo Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor

Identification of splenic reservoir monocytes and their deployment to inflammatory sites

Getting to the heart of intracellular glucocorticoid regeneration: 11β-HSD1 in the myocardium

Pharmacological therapy can increase capillary density in post-infarction remodeled rat hearts

Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning

Inhibition of COX pathway in experimental myocardial infarction

Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AM

High dose aspirin and left ventricular remodeling after myocardial infarction: aspirin and myocardial infarction

Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation

The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions

P31

scholarly article

P356

10.1111/BPH.14155

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Nikolaos G Frangogiannis

P577

2018-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29394499

http://www.w3.org/2001/XMLSchema#string

P921

inflammation

Aat atak

P932

5901181

http://www.w3.org/2001/XMLSchema#string

Anti-inflammatory therapies in myocardial infarction: failures, hopes, and challenges.

about

P2860

P2860

Anti-inflammatory therapies in myocardial infarction: failures, hopes, and challenges.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P921

P932